162 related articles for article (PubMed ID: 16847437)
1. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
Kelley SK; Gelzleichter T; Xie D; Lee WP; Darbonne WC; Qureshi F; Kissler K; Oflazoglu E; Grewal IS
Br J Pharmacol; 2006 Aug; 148(8):1116-23. PubMed ID: 16847437
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS
Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310
[TBL] [Abstract][Full Text] [Related]
3. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.
Francisco JA; Donaldson KL; Chace D; Siegall CB; Wahl AF
Cancer Res; 2000 Jun; 60(12):3225-31. PubMed ID: 10866315
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys.
Ma A; Dun H; Song L; Hu Y; Zeng L; Bai J; Zhang G; Kinugasa F; Miyao Y; Sakuma S; Okimura K; Kasai N; Daloze P; Chen H
Transplantation; 2014 Feb; 97(4):397-404. PubMed ID: 24389907
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Tai YT; Catley LP; Mitsiades CS; Burger R; Podar K; Shringpaure R; Hideshima T; Chauhan D; Hamasaki M; Ishitsuka K; Richardson P; Treon SP; Munshi NC; Anderson KC
Cancer Res; 2004 Apr; 64(8):2846-52. PubMed ID: 15087402
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
Ryan MC; Palanca-Wessels MC; Schimpf B; Gordon KA; Kostner H; Meyer B; Yu C; Van Epps HA; Benjamin D
Blood; 2017 Nov; 130(18):2018-2026. PubMed ID: 28903943
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
[TBL] [Abstract][Full Text] [Related]
8. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
Lapalombella R; Gowda A; Joshi T; Mehter N; Cheney C; Lehman A; Chen CS; Johnson AJ; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
Br J Haematol; 2009 Mar; 144(6):848-55. PubMed ID: 19183192
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2.
Lee WS; Shim SR; Lee SY; Yoo JS; Cho SK
Drug Des Devel Ther; 2018; 12():495-504. PubMed ID: 29563774
[TBL] [Abstract][Full Text] [Related]
10. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.
Oflazoglu E; Stone IJ; Brown L; Gordon KA; van Rooijen N; Jonas M; Law CL; Grewal IS; Gerber HP
Br J Cancer; 2009 Jan; 100(1):113-7. PubMed ID: 19066610
[TBL] [Abstract][Full Text] [Related]
11. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
Funakoshi S; Longo DL; Murphy WJ
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
[TBL] [Abstract][Full Text] [Related]
12. Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody.
Kasai N; Yoshikawa Y; Enokizono J
MAbs; 2014; 6(5):1220-8. PubMed ID: 25517307
[TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40.
Francisco JA; Schreiber GJ; Comereski CR; Mezza LE; Warner GL; Davidson TJ; Ledbetter JA; Siegall CB
Blood; 1997 Jun; 89(12):4493-500. PubMed ID: 9192773
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody.
Ristov J; Espie P; Ulrich P; Sickert D; Flandre T; Dimitrova M; Müller-Ristig D; Weider D; Robert G; Schmutz P; Greutmann B; Cordoba-Castro F; Schneider MA; Warncke M; Kolbinger F; Cote S; Heusser C; Bruns C; Rush JS
Am J Transplant; 2018 Dec; 18(12):2895-2904. PubMed ID: 29665205
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody.
Muralidharan S; Njenga M; Garron T; Bondensgaard K; Paolini JF
J Pharmacol Exp Ther; 2022 Apr; 381(1):12-21. PubMed ID: 35078863
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes.
Murphy WJ; Funakoshi S; Beckwith M; Rushing SE; Conley DK; Armitage RJ; Fanslow WC; Rager HC; Taub DD; Ruscetti FW
Blood; 1995 Sep; 86(5):1946-53. PubMed ID: 7544649
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
[TBL] [Abstract][Full Text] [Related]
19. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.
Gladue RP; Paradis T; Cole SH; Donovan C; Nelson R; Alpert R; Gardner J; Natoli E; Elliott E; Shepard R; Bedian V
Cancer Immunol Immunother; 2011 Jul; 60(7):1009-17. PubMed ID: 21479995
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune response to a CD40 agonist antibody in nonhuman primates.
Caudell DL; Dugan GO; Babitzki G; Schubert C; Braendli-Baiocco A; Wasserman K; Acona G; Stern M; Passioukov A; Cline JM; Charo J
J Leukoc Biol; 2024 May; 115(6):1084-1093. PubMed ID: 38372596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
